Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

English

Regional settings

Entity•Capital Com UK LimitedAuthorised and regulated by the Financial Conduct Authority (FCA)

My account

Home Markets SharesDexCom, Inc.

Trade DexCom, Inc. - DXCM CFD

Summary Historical Data

Trading Conditions

Spread

0.22

Long position overnight fee

Long position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	-0.026179 % (-$1.05)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

-0.026179%

Short position overnight fee

Short position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	0.003957 % ($0.16)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

0.003957%

Overnight fee time

21:00 (UTC)

Currency

USD

Min traded quantity

Margin

Stock exchange

United States of America

Commission on trade¹

¹Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats

Prev. Close	127.32
Open	126.4
1-Year Change	3.96%
Day's Range	123.76 - 128.44

DexCom Company profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.